<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ephedrine and guaifenesin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ephedrine and guaifenesin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ephedrine and guaifenesin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="96687" href="/d/html/96687.html" rel="external">see "Ephedrine and guaifenesin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F12864124"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bronkaid [OTC] [DSC];</li>
<li>Primatene Asthma [OTC] [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F25590104"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Expectorant/Decongestant</li></ul></div>
<div class="block doa drugH1Div" id="F57156742"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18e0f82e-9f84-425a-9cc1-60288d6af10a">Asthma, mild intermittent symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, mild intermittent symptoms: Note:</b> Although included as an FDA-approved use in the manufacturer's prescribing information for the temporary relief of mild symptoms of intermittent asthma, nonselective beta agonists or oral beta-2 agonists (including oral ephedrine/guaifenesin) are not recommended due to their potential for excessive cardiac stimulation, especially in high doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.1'])">Ref</a></span>). All products (ie, Bronkaid, Primatene Asthma) have been discontinued in the United States &gt;1 year.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ephedrine 12.5 mg/guaifenesin 200 mg:</b>
<b>Oral:</b> 1 to 2 tablets every 4 hours as needed; maximum dose: 12 tablets (ephedrine 150 mg/guaifenesin 2.4 g) per 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Ephedrine 25 mg/guaifenesin 400 mg:</b>
<b>Oral:</b> 1 tablet every 4 hours as needed; maximum dose: 6 tablets (ephedrine 150 mg/guaifenesin 2.4 g) per 24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F57168505"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;">There are no dosage adjustment provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F57168506"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;">There are no dosage adjustment provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F26428278"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Hypertension, tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Emotional disturbance, headache, insomnia, nervousness, seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Cough, exacerbation of asthma, productive cough</p></div>
<div class="block coi drugH1Div" id="F25468694"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use if asthma is not confirmed by a health care provider; coadministration with a monoamine oxidase inhibitor (MAOI) or 2 weeks after discontinuing an MAOI; hypersensitivity to ephedrine, guaifenesin, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F25468695"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effect: May cause hypertension or tachycardia, increasing the risk of myocardial infarction (MI) and/or stroke. Serious cardiovascular events (eg, MI, stroke, arrhythmias), including deaths, have been previously reported with use of dietary supplements containing ephedra alkaloids (Haller, 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Only use with a diagnosis of asthma; notify health care provider if asthma becomes worse during use. Inhaled bronchodilators provide more rapid symptomatic relief of asthma than ephedrine/guaifenesin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart disease and/or hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with narrow angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric conditions: Use with caution in patients with psychiatric or emotional conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Use with caution in patients with thyroid disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Not for OTC use in children &lt;12 years.</p></div>
<div class="block foc drugH1Div" id="F25562598"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bronkaid: Ephedrine sulfate 25 mg and guaifenesin 400 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Primatene Asthma: Ephedrine sulfate 12.5 mg and guaifenesin 200 mg [DSC] [scored]</p></div>
<div class="block geq drugH1Div" id="F28604065"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F28651456"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Bronkaid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25-400 mg (per each): $0.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Primatene Asthma Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5-200 mg (per each): $0.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F25468705"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer without regard to food.</p></div>
<div class="block use drugH1Div" id="F57168504"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;">
<b>Asthma, mild intermittent symptoms:</b> Although included as an FDA-approved use in the manufacturer's prescribing information for the temporary relief of mild symptoms of intermittent asthma, nonselective beta agonists or oral beta-2 agonists (including oral ephedrine/guaifenesin) are not recommended due to their potential for excessive cardiac stimulation, especially in high doses (GINA 2023; NAEPP 2007).</p></div>
<div class="block cyt drugH1Div" id="F13299268"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F13120073"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alkalinizing Agents: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atropine (Systemic): May enhance the therapeutic effect of EPHEDrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May diminish the therapeutic effect of EPHEDrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bretylium: May enhance the therapeutic effect of Alpha-/Beta-Agonists (Direct-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: EPHEDrine (Systemic) may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloNIDine: May enhance the therapeutic effect of EPHEDrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): EPHEDrine (Systemic) may decrease the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Droxidopa: EPHEDrine (Systemic) may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: Decongestants may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Do not use hyaluronidase to enhance the dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: EPHEDrine (Systemic) may enhance the arrhythmogenic effect of Inhalational Anesthetics. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Alpha-/Beta-Agonists (Indirect-Acting) may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Ethanol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: May enhance the hypertensive effect of EPHEDrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propofol: May enhance the therapeutic effect of EPHEDrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May diminish the therapeutic effect of EPHEDrine (Systemic). EPHEDrine (Systemic) may diminish the therapeutic effect of QuiNIDine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May diminish the therapeutic effect of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rocuronium: EPHEDrine (Systemic) may enhance the therapeutic effect of Rocuronium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline: May enhance the stimulatory effect of EPHEDrine (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urinary Acidifying Agents: May decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Alpha-/Beta-Agonists (Direct-Acting) may enhance the hypertensive effect of Vasopressin. The effect of other hemodynamic parameters may also be enhanced. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F54814515"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Refer to individual monographs.</p></div>
<div class="block brc drugH1Div" id="F54814516"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual monographs.</p></div>
<div class="block pha drugH1Div" id="F25468697"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Ephedrine: Releases tissue stores of norepinephrine and thereby produces an alpha- and beta-adrenergic stimulation; longer-acting and less potent than epinephrine</p>
<p style="text-indent:-2em;margin-left:2em;">Guaifenesin: Thought to act as an expectorant by irritating the gastric mucosa and stimulating respiratory tract secretions, thereby increasing respiratory fluid volumes and decreasing mucous viscosity</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F25576757"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bronkaid dual action</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alcough</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Bronkaid (ephedrine/guaifenesin) [prescribing information]. Pittsburgh, PA: Foundation Consumer Healthcare LLC; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11117974">
<a name="11117974"></a>Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.<i> N Engl J Med</i>. 2000;343(25):1833-1838.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ephedrine-and-guaifenesin-drug-information/abstract-text/11117974/pubmed" id="11117974" target="_blank">11117974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.1">
<a name="NAEPP.1"></a>National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel on the Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href="http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf" target="_blank">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Accessed July 25, 2019.</div>
</li>
<li>
<div class="reference">
                  Primatene (ephedrine/guaifenesin) [prescribing information]. Madison, NJ: Pfizer Consumer Healthcare; 2013.</div>
</li></ol></div><div id="topicVersionRevision">Topic 96479 Version 133.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
